Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions
Restricted accessResearch articleFirst published online December, 2016
Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions
European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV in primary care was a cross-sectional survey carried out by the European Society of Cardiology, EURObservational Research Programme in 2014–2015 in 71 centres from 14 European countries. The main objective was to determine whether the 2012 Joint European Societies’ guidelines on cardiovascular disease (CVD) prevention in people at high CVD risk have been followed in clinical practice.
Methods
Patients without a history of atherosclerotic disease started on either blood pressure and/or lipid and/or glucose-lowering treatments were identified and interviewed at least six months after the start of medication.
Results
Medical notes of 6700 patients were reviewed, and 4579 patients (58.7% women; mean age 58.8 (standard deviation (SD) 11.3) years) interviewed (interview rate 68.3%). Overall, 16.6% were smokers, 39.9% were overweight (body mass index (BMI)≥25 and <30 kg/m2), 43.5% obese (BMI ≥30 kg/m2) and 63.9% centrally obese (waist circumference of ≥88 cm for women, ≥102 cm for men). The medical risk factor control was very poor, with less than half (42.8%) of the patients on blood pressure lowering medication reaching the target of <140/90 mm Hg (<140/80 mm Hg in people with self-reported diabetes). Among treated dyslipidaemic patients only 32.7% attained the low-density lipoprotein (LDL)-cholesterol target of <2.5 mmol/l. Among people treated for type 2 diabetes mellitus, 58.5% achieved the glycated haemoglobin (HbA1c) target of <7.0%.
Conclusion
The EUROASPIRE IV survey shows that large proportions of patients at high CVD risk have unhealthy lifestyle habits and uncontrolled blood pressure, lipids and diabetes. The present data make it clear that more efforts must be taken to improve cardiovascular prevention in people at high CVD risk.
PerkJDe BackerGGohlkeH. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J2012; 33: 1635–1701.
2.
European Society of Cardiology. Preventing coronary heart disease. A guide for the practising physician. Assen, the Netherlands: Van Gorcum, 1978.
3.
PyöräläKDe BackerGGrahamI. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerotic Society and European Society of Hypertension. Eur Heart J1994; 15: 1300–1331.
4.
WoodDDe BackerGFaergemanD. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J1998; 19: 1434–1503.
5.
De BackerGAmbrosioniEBorch-JohnsenK. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehab2003; 10: S1–S78.
6.
GrahamIAtarDBorch-JohnsenK. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehab2007; 14: S1–S113.
7.
EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J1997; 18: 1569–1582.
8.
EUROASPIRE Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Euro Heart Survey Programme. Eur Heart J2001; 22: 554–572.
9.
EUROASPIRE Study Group. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. Lancet2001; 357: 995–1001.
10.
KotsevaKWoodDDe BackerG. on behalf of EUROASPIRE III Study Group. EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehab2009; 16: 121–137.
11.
KotsevaKWoodDDe BackerG. on behalf of EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: A comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet2009; 373: 929–940.
12.
KotsevaKWoodDDe BackerG. on behalf of EUROASPIRE study Group. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high risk subjects in general practice: Cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehab2010; 17: 530–540.
13.
KotsevaKWoodDDe BacquerD. on behalf of the EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from twenty four European countries. Eur J Prev Card. 2016; 23: 636–648.
14.
KotsevaKRydénLDe BackerG. EURObservational Research Programme: EUROASPIRE survey of cardiovascular prevention and diabetes in 24 countries in Europe. Eur Heart J2015; 36: 950–955.
15.
KotsevaKDe BacquerDJenningsC. on behalf of EUROASPIRE Investigators. Adverse lifestyle trends counter improvements in cardiovascular risk factor management in coronary patients: Results from three EUROASPIRE cross sectional surveys 1999 – 2013 of the European Society of Cardiology. JACC2015; 66: 1633–1636.
16.
LeanMEJHanTSMorrisonCE. Waist circumference as a measure for indicating need for weight management. Br Med J1995; 311: 158–161.
17.
MiddletonETMoriceAH. Breath carbon monoxide as an indication of smoking habit. Chest2000; 117: 758–763.
18.
FriedewaldWTLevyRIFredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem1972; 18: 499–502.
19.
WuPWilsonKDimoulasP. Effectiveness of smoking cessation therapies: A systematic review and meta-analysis. BMC Public Health2006; 6: 300–300.
20.
KromhoutDMenottiAKestelootH. Prevention of coronary heart disease by diet and lifestyle: Evidence from prospective cross-cultural, cohort, and intervention studies. Circulation2002; 105: 893–898.
21.
Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Meta-analysis of randomised trials. Br Med J2008; 336: 1121–1123.
22.
LawMRMorrisJKWaldNJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J2009; 338: b1665–b1665.
23.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet2008; 371: 117–125.
24.
BrugtsJJYetginTHoeksSE. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomised controlled trials. Br Med J2009; 338: b2376–b2376.
25.
RydénLGrantPJAnkerSD. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J2013; 34: 3035–3087.
26.
BanegasJRLopez-GarciaEDallongevilleJ. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: The EURIKA study. Eur Heart J2011; 32: 2143–2152.
27.
LudlSPetekDLauxG. Recording of risk factors and lifestyle counselling in patients at high rsk for cariovascular disease in European primary care. Eur J Prev Card2011; 19: 258–266.
28.
GiampaoliSPalmieriLDonfrancescoC. Osservatorio Epidemiologico Cardiovascolare/Health Examination Survey Research Group: Cardiovascular health in Italy. Ten-year surveillance of cardiovascular diseases and risk factors: Osservatorio Epidemiologico Cardiovascolare/Health Examination Survey 1998-2012. Eur J Prev Card2015; 22: S9–S37.
29.
Wolf-MaierKCooperRSKramerH. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension2004; 43: 10–17.
30.
WongNDPataoCWongK. Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: Comparison by prevalent cardiovascular disease status. Diab Vasc Dis Res2013; 10: 505–513.
31.
Van GanseELaforestLAlemaoE. Lipid-modifying therapy and attainment of cholesterol goals in Europe: The Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opinion2005; 21: 1389–1399.
32.
HajjarIKotchenTA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA2003; 290: 199–206.
33.
GuQBurtVLDillonCF. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: The National Health And Nutrition Examination Survey, 2001 to 2010. Circulation2012; 126: 2105–2114.
34.
GhandeharyHKamal-BahlSWongND. Prevalence and extent of dyslipidaemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003–2004. Am Heart J2008; 156: 112–119.
35.
CullenMWSteinJHGangnonR. National improvements in low-density lipoprotein cholesterol management of individuals at high coronary risk: National Health and Nutrition Examination Survey, 1999 to 2002. Am Heart Journal2008; 156: 284–291.
